BrainStorm Cell Therapeutics

A clinical-stage biotechnology company developing cell and exosome therapies for neurodegenerative diseases. Its NurOwn platform uses autologous MSC-NTF cells, manufactured individually from a patient's bone marrow and delivered by intrathecal injection. The company describes a process of harvesting bone marrow, differentiating it into MSC-NTF cells, and administering the resulting therapy. NurOwn, also called debamestrocel, is investigational and has not been approved by the FDA or another regulatory authority. BrainStorm is also developing an allogeneic exosome platform designed to deliver therapeutic proteins and nucleic acids. The exosome approach is not patient-specific and may allow non-invasive repeat dosing. Its work includes clinical studies in ALS, while the exosome platform remains preclinical. The company provides information for patients and caregivers, investors, media, and potential business development and licensing partners.